Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Rating of “Buy” by Brokerages
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has received an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock […]
Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has received an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued a report on the stock […]
